Bicara Therapeutics is progressing its Phase 3 trial of ficerafusp alfa for head and neck cancer, expecting interim results by mid-2027 that could support accelerated approval. The company holds nearly $500 million in cash and securities, funding operations into early 2029. Despite a Q2 net loss of $55.4 million, analysts remain optimistic, raising price targets to $35 and $39. This financial strength and clinical progress position Bicara as a promising player in cancer therapy development.
Vicor is rated as a 'Buy' with a price target of $846 per share by 2033, driven by its advanced Vertical Power Delivery (VPD) technology that aligns with next-gen AI data center needs. The company aims to nearly quintuple its revenue from $470 millio...
Southwest Airlines is rated a buy with an expected 15-20% upside driven by a commercial overhaul that has led to record unit revenue growth and a resilient profit mix. The airline's transformation into a merchandised model with new fare structures an...
Walhalla Gold Corp. has appointed Owen Greenberger as Vice-President of Exploration to enhance its exploration efforts across its Victorian precious and critical minerals portfolio. Greenberger brings nearly 20 years of Australian exploration experie...
NEAR Protocol's token price surged about 80% in seven days, reaching $4.29, driven by Bitcoin's rally past $86,000 and strong institutional interest. The NEAR Intents platform saw $29.3 billion in cumulative transaction volume and over $200 million i...
Kingfisher PLC shares rose as much as 10.6% following a strong first-half profit performance driven by improved margins. The company upgraded its annual profit forecast to £595-635 million, up from £565-625 million, and raised free cash flow guidance...
